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ABSTRACT
Globally, chronic kidney disease (CKD) is an emerging public health challenge but accurate data on its true prevalence are
scarce, particularly in poorly resourced regions such as sub-Saharan Africa (SSA). Limited funding for population-based
studies, poor laboratory infrastructure and the absence of a validated estimating equation for kidney function in Africans
are contributing factors. Consequently, most available studies used to estimate population prevalence are hospital-based,
with small samples of participants who are at high risk for kidney disease. While serum creatinine is most commonly used
to estimate glomerular filtration, there is considerable potential bias in the measurement of creatinine that might lead to
inaccurate estimates of kidney disease at individual and population level. To address this, the Laboratory Working Group of
the National Kidney Disease Education Program published recommendations in 2006 to standardize the laboratory
measurement of creatinine. The primary objective of this review was to appraise implementation of these
recommendations in studies conducted in SSA after 2006. Secondary objectives were to assess bias relating to choice of
estimating equations for assessing glomerular function in Africans and to evaluate use of recommended diagnostic criteria
for CKD. This study was registered with Prospero (CRD42017068151), and using PubMed, African Journals Online and Web of
Science, 5845 abstracts were reviewed and 252 full-text articles included for narrative analysis. Overall, two-thirds of studies
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did not report laboratory methods for creatinine measurement and just over 80% did not report whether their creatinine
measurement was isotope dilution mass spectroscopy (IDMS) traceable. For those reporting a method, Jaffe was the most
common (93%). The four-variable Modification of Diet in Renal Disease (4-v MDRD) equation was most frequently used (42%),
followed by the CKD Epidemiology Collaboration (CKD-EPI) equation for creatinine (26%). For the 4-v MDRD equation and CKD-EPI
equations, respectively, one-third to one half of studies clarified use of the coefficient for African-American (AA) ethnicity. When
reporting CKD prevalence,<15% of studies fulfilled Kidney Disease: Improving Global Outcomes criteria and even fewer used a
population-based sample. Six studies compared performance of estimating equations to measured glomerular filtration rate
(GFR) demonstrating that coefficients for AA ethnicity used in the 4-v MDRD and the CKD-EPI equations overestimated GFR in
Africans. To improve on reporting in future studies, we propose an ‘easy to use’ checklist that will standardize reporting of kidney
function and improve the quality of studies in the region. This research contributes some understanding of the factors requiring
attention to ensure accurate assessment of the burden of kidney disease in SSA. Many of these factors are difficult to address and
extend beyond individual researchers to health systems and governmental policy, but understanding the burden of kidney
disease is a critical first step to informing an integrated public health response that would provide appropriate screening,
prevention and management of kidney disease in countries from SSA. This is particularly relevant as CKD is a common pathway
in both infectious and non-communicable diseases, and multimorbidity is now commonplace, and even more so when those
living with severe kidney disease have limited or no access to renal replacement therapy.
Keywords: albuminuria, chronic kidney disease, creatinine, estimated and measured glomerular filtration rate, prevalence,
systematic review
INTRODUCTION
In sub-Saharan Africa (SSA), a double burden of infectious and
non-communicable diseases contributes to a potentially high
risk for chronic kidney disease (CKD). However, the true preva-
lence of CKD remains difficult to quantify [1, 2]. A systematic re-
view of the epidemiology of CKD in SSA concluded that most
studies were of medium to low quality due to poor sampling
methods and unreliable laboratory measurements of kidney
function [1]. Many of these studies were conducted in urban
hospitals with participants who had multiple risk factors for
CKD, and proteinuria was the most common measure of kidney
function [1]. Given that convenience sampling may lead to over-
estimating the burden of CKD at population level, and that the
diagnostic criteria used to define CKD were sub-optimal in
many of the studies from the review, the reasons for this low re-
search quality merit consideration.
First, the funding and infrastructure required for population-
based CKD prevalence studies is substantial and, even in the most
well-resourced environments, conducting these studies is chal-
lenging [2]. Second, in the absence of validated, affordable, point of
care diagnostics for kidney disease, for studies to conform to the
internationally accepted Kidney Disease: Improving Global
Outcomes (KDIGO) guidelines requires (i) laboratory measurement
of serum creatinine using an isotope dilution mass spectroscopy
(IDMS)-traceable standard reference material for creatinine; (ii) cal-
culation of the glomerular filtration rate (GFR) using the serum cre-
atinine; (iii) measurement of urine protein or albumin from a spot
urine sample, preferably laboratory quantified as an albumin:crea-
tinine ratio; and (iv) in the absence of clinical evidence that con-
firms chronicity, repeating these serum and urine measurements
after a minimum period of 3 months [3, 4]. These requirements im-
pose substantial logistic, infrastructural and financial hurdles for
clinical researchers, particularly in resource-limited settings where
the burden of CKD is projected to be highest.
For any study using KDIGO criteria, access to accurate diag-
nostic laboratory services is essential as even small variations
in creatinine measurement can impact on population preva-
lence estimates [2]. This is underappreciated by clinician scien-
tists and may reflect poor interdisciplinary collaboration with
chemical pathologists. For example, the older colorimetric picric
acid (Jaffe) method is less accurate but cheaper than the recently
developed enzymatic method. While the enzymatic method is
recommended, in SSA most laboratories use the Jaffe method, for
which a correction factor should be applied [1]. To reduce inter-
laboratory measurement bias, the Laboratory Working Group of
the National Kidney Disease Education Program (NKDEP) in the
USA published guidelines in 2006 that recommended use of an
IDMS-traceable standard reference material for creatinine mea-
surement [5]. Consequently, the four-variable Modification of
Diet in Renal Disease (4-v MDRD) equation was re-expressed for
IDMS-traceability and the CKD Epidemiology Collaboration (CKD-
EPI) equations are based on the use of an IDMS-traceable method
[6, 7]. Adherence to standard internal and external quality assur-
ance procedures are additional obligatory steps that mitigate
laboratory-induced bias. In SSA and other low and middle income
settings, reliable diagnostic laboratory infrastructure cannot be
assumed. The lack of study-specific standardization in sampling
and measurement of creatinine is considered the greatest obsta-
cle to determining the global prevalence of CKD [2, 8].
Further bias may be introduced through the choice of esti-
mating equation for GFR. Initially, the National Kidney
Foundation guidelines recommended the 4-v MDRD equation
for estimating GFR [3]. This equation was derived from a rela-
tively small study sample in the USA with a coefficient that cor-
rected for a higher creatinine observed in African-Americans
(AAs). A similar correction coefficient for AA ethnicity was de-
rived for use with the CKD-EPI equation, which is now the pre-
ferred equation in the revised KDIGO guidelines for 2014 [4]. In
studies from SSA, when the coefficients for AA ethnicity are
used for either of these two equations, they consistently overes-
timate GFR [9–15]. In the absence of appropriate, validated esti-
mating equations for African populations, some studies have
omitted the coefficients for AA ethnicity when using the 4-v
MDRD and CKD-EPI equations [16, 17]. Researchers need to be
cognizant of the limitations imposed by these equations and
the bias that could be introduced into their results.
The primary objective of this review was to appraise report-
ing of laboratory methods for creatinine measurement in stud-
ies utilizing creatinine to assess kidney function in SSA. The
secondary objectives were to assess bias relating to: choice of
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equations used to estimate GFR; use of coefficients for AA eth-
nicity for the 4-v MDRD and CKD-EPI equations; criteria used to
diagnose CKD; and study design and sampling strategies.
MATERIALS ANDMETHODS
Search strategy and selection criteria
This narrative systematic review was registered with the
International Prospective Register of Systematic Reviews
(PROSPERO) (CRD42017068151) and completed according to the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) together with the revised quality assessment
of diagnostic accuracy studies (QUADAS-2) guidelines [18–20].
The period selected for review included all original research
studies published from 31 January 2008 to 31 December 2018.
This was based on the assumption that after the NKDEP guide-
lines were published in 2006, this would set the standard for the
widespread implementation of IDMS-traceable creatinine
assays in diagnostic laboratories by 2008—and we would see a
similar trend in studies from SSA [5]. For studies that deter-
mined the prevalence of CKD, the recommended criteria for di-
agnosis of CKD were first published in 2002 and subsequently
updated in 2012 [3, 4]. Likewise, we anticipated that these guide-
lines would inform the choice of criteria for clinical studies.
The online databases for PubMed, African Journals Online and
Web of Science were searched using the relevant medical sub-
ject headings (Supplementary data, Appendix S1). Based on the
title and abstract, all studies from the SSA region that assessed
kidney function in adults were evaluated according to inclusion
and exclusion criteria agreed upon by the team conducting the
systematic review (Supplementary data, Appendix S1). Only
those abstracts with studies with full-text articles, available in
English, were selected for the final analysis.
Quality assessment and data extraction
The online database search generated abstracts for screening.
J.A.G. and M.v.D. independently screened abstracts from African
Journals Online and Web of Science. There were no additional refer-
ences identified through bibliography searches. Results were com-
pared and differences of opinion referred to J.F. or H.R.E. Similarly,
J.F. and H.R.E. independently screened abstracts from PubMed and
followed the same process with differences referred to J.A.G. and
M.v.D. Duplicates were removed and the team agreed on a list of
eligible abstracts for which full-text articles were sourced by J.A.G.
and H.R.E. For each full-text article, data were extracted by two
authors who worked independently (J.F., J.A.G., H.R.E., M.v.D. and
R.K.). Each author then compared their data extraction to the sec-
ond author and discrepancies were resolved or referred to the
remaining authors for review. If needed, J.F. contacted authors via
email for clarification of study-specific information and incorpo-
rated the feedback for those who responded.
The QUADAS-2 assessment sheet (Supplementary data,
Appendix S2) was used as a template by the team to pilot the
data extraction process. After conducting the pilot, a revised
form, adapted for the specific needs of this study, was gener-
ated and accepted by the group for use. This was formulated
into a study-specific data extraction sheet (Supplementary data,
Appendix S3). In summary, where appropriate for each full-text
study, the data were abstracted as follows: (i) was GFR mea-
sured or estimated, and by which method; (ii) was creatinine
measured, and by which method, and was the method IDMS-
traceable to a standard reference material for creatinine; (iii)
was cystatin C measured; (iv) did the study determine CKD
prevalence—if so, by which criteria, was chronicity confirmed
with repeat measurements; and (v) study design, sample selec-
tion and sample size. The estimating equations for creatinine,
cystatin and creatinine-cystatin, and CKD criteria are defined in
Supplementary data, Appendix S4. Data were analyzed using
simple descriptive statistics including frequency and percent-
age tabulation for continuous variables. A narrative analysis
was considered more appropriate for the aim of this systematic
review and a meta-analysis was therefore not conducted.
Performance of eGFR equations
For those studies with measured GFR (mGFR) and comparisons
of performance of the different estimated GFR (eGFR) equations,
the relative performance of these equations was assessed using:
(i) bias: median of difference between estimated and mGFR; 95%
confidence interval (CI), when available; and (ii) P30: percentage
of eGFR values within 30% of the (gold standard) mGFR; 95% CI,
when available.
RESULTS
From the online database searches, there were 5845 records
published during the review period. The procedure followed for
study identification and selection is summarized in Figure 1.
The final number of full-text articles assessed as eligible for in-
clusion into this systematic review totaled 252 (Supplementary
data, Appendix S5). The results are presented as follows: (i) lab-
oratory method for creatinine measurement; (ii) estimating
equations for eGFR; (iii) mGFR using a gold standard method,
comparison of the performance of eGFR equations in relation to
mGFR and the impact of coefficients for AA ethnicity; (iv) diag-
nostic criteria for CKD; and (v) quality of the studies.
Laboratory method for creatinine measurement
The laboratory method for creatinine measurement was not
reported in two-thirds of studies (159/252; 63.1%). For those that
included a method, the Jaffe method was by far the most com-
mon (80/86; 93.0%). Only six studies described an enzymatic
method. Most studies (206/252; 81.7%) did not state whether their
laboratory was using an IDMS-traceable standard reference ma-
terial for creatinine measurement. When stipulated, IDMS-
traceable assays were more common (34/39; 87.2%) than non-
IDMS traceable assays, of which there were only five (Table 1).
Estimating equations for GFR
Most studies used an estimating equation to assess kidney func-
tion (231/252; 91.6%) and some used more than one, so that eGFR
equations were used in 363 instances. Of the available equations,
the 4-v MDRD was most frequently used (146/363; 40.2%), fol-
lowed by the CKD-EPI equation for creatinine (94/363; 25.9%) and
Cockcroft–Gault (85/363; 23.4%). When the 4-v MDRD equation
was used, one-third used the 4-v MDRD re-expressed for IDMS
traceability (46/146; 31.5%), half did not stipulate which version
was used (74/146; 50.7%) and the remainder used the original 4-v
MDRD (prior to the introduction of an IDMS-traceable standard
reference material for creatinine). The AA coefficient was used
for a third of the 4-v MDRD equations (45/146; 30.8%) and almost
half (72/146; 49.3%) did not stipulate if this was used. For the
CKD-EPI creatinine equation, more studies used the AA coeffi-
cient (39/94; 41.5%) and a quarter did not clarify if this was used
(23/94; 24.5%) (Table 1 and Supplementary data, Appendix S4).
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mGFR using a gold standard method, comparison of the
performance of eGFR equations in relation to mGFR and
the impact of coefficients for AA ethnicity
There were 10 studies that measured GFR using a gold stan-
dard reference method, 4 from South Africa and 1 each from
the Democratic Republic of the Congo, Ghana, Ivory Coast,
Kenya, Seychelles and Sudan [9–13, 15, 22–25]. The Kenyan
study and one study from South Africa focused on adult par-
ticipants with HIV infection [12, 13]. This was particularly rele-
vant for the SSA region because of widespread use of
tenofovir-containing antiretroviral therapy regimens as first-
line treatment. The methods used to measure GFR included
iohexol on dried blood spots, iohexol plasma excretion,
technetium-99m diethylenetriamine penta-acetic acid (DTPA),
chromium-51 ethylenediamine tetra-acetic acid (EDTA), inulin
and 24-h urinary creatinine clearance. Six studies compared
the performance of currently recommended eGFR equations to
a reference mGFR method. The impact of using the coefficient
for AA ethnicity for the 4-v MDRD and CKD-EPI equations was
also evaluated. Overall, most studies demonstrated that when
compared with the mGFR method that was used, inclusion of
the coefficient for AA ethnicity resulted in overestimation of
eGFR in Africans (Table 2). Some studies compared the
relative performance of one or more eGFR equations without
reference to a gold standard mGFR. Since the scientific validity
of this practice is unsubstantiated, no further analysis was
conducted.
Diagnostic criteria for CKD
Most studies (162/252; 64.5%) defined CKD using a broad range
of criteria that have been summarized in Table 3. Fewer than
15% of studies confirmed chronicity by repeating the out of
range test for eGFR and/or albuminuria/proteinuria after the
minimum recommended period of 3 months, a requirement
for diagnosing CKD as per KDIGO guidelines. Notably, most
studies that fulfilled the KDIGO requirements were published in
the latter half of the period under review [26–38].
FIGURE 1: Flowchart for study identification and selection.
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Quality of studies
Most study designs were cross-sectional (172/252; 68.3%), fewer
were case-controlled (41/252; 16.3%) and the methodology was
unclear in the remainder (39/252; 15.4%). Many studies reported
‘prevalent’ CKD, but this was restricted to hospital- or clinic-
based convenience samples and often focused on participants
at high risk for kidney disease, for example, those with sickle
cell disease, diabetes, hypertension, obesity, HIV and cardiac
failure. For true population prevalence of CKD, there were eight
randomly sampled population-based studies that determined
prevalent CKD [10, 17, 39–44]. None of the population-based
studies reported incident CKD.
DISCUSSION
There is scope for improving the quality of studies on kidney
function in SSA. This includes aspects of study design and
sampling, reporting of laboratory methods for creatinine mea-
surement and IDMS traceability, detailing choices for GFR equa-
tions that include coefficients for AA ethnicity, and diagnosing
CKD using appropriate criteria. While this is the first review of
its kind for SSA, similar findings have been reported in Europe,
Mexico, Uruguay and India [8, 45].
There are published NKDEP guidelines for the laboratory
reporting of creatinine; however, two-thirds of our studies did
not report the method of creatinine measurement and even
fewer reported whether the method was IDMS-traceable to a
standard reference material for creatinine. This limited insights
into the extent of implementation of laboratory standards for
creatinine-based testing of kidney function, but our findings re-
flect a need for better study-specific interdisciplinary collabora-
tion between chemical pathologists, epidemiologists, public
health and clinical scientists. Collaboration would deepen the
scientific rationale and strengthen the methodological compo-
nents of studies that characterize kidney disease, particularly at
population level.
Many studies applied an estimating equation for GFR, but it
is noteworthy that Cockcroft–Gault was still relatively fre-
quently used, despite its omission from clinical practice guide-
lines since 2002. Perhaps this is due to the long history of this
equation and its ease of use in clinical settings. Because of the
time period for this review, it would be expected, as we have
confirmed, that the 4-v MDRD equation was the most fre-
quently used equation, but most studies did not identify which
version of the equation was used in relation to IDMS traceabil-
ity. Depending on which equation was used [CKD-EPI(serum
creatinine, SCr) and/or 4-v MDRD], up to half of studies did not
state whether the coefficients for AA ethnicity were used. In
this regard, two recent studies from the Democratic Republic of
the Congo and Ivory Coast (both using iohexol plasma excre-
tion to measure GFR) deserve mention. The former, supporting
prior findings from South and Eastern Africa, confirmed that
omitting coefficients for AA ethnicity with CKD-EPI(SCr) and 4-
v MDRD equations improved accuracy. Together, these studies
highlight the critical importance of validating eGFR equations
in populations in which they are recommended for use [9, 12,
13, 15]. The Ivorian study goes a few steps further, where for
the first time in West Africans, normal reference ranges for
GFR are now available and the performance of the Full Age
Spectrum for creatinine (FAScreat) equation was validated.
Originally derived from northern Caucasian populations, the
FAScreat equation incorporates adjustment for age and gender
as a Q value. In the Ivorian study, using Q values derived for
West Africans, the performance of FAScreat was better than
CKE-EPI(SCr) and requires no adjustment for ethnicity [25, 46].
If the FAScreat equation is validated in other regions of SSA
and proven to be superior to the currently recommended CKD-
EPI(SCr) equation, this provides strong support for changing
current eGFR equations recommended for use in KDIGO clinical
practice guidelines [4]. More broadly, remembering that perfor-
mance of CKD-EPI(SCr) has been questioned in Asia, it is in-
cumbent on policy makers—including KDIGO, to prioritize use
of validated population-appropriate eGFR equations particu-
larly when relating to diagnosis of CKD—given the global
health implications [46, 47].
The gold standard reference methods used for mGFR also re-
quire some reflection due to the potential biases that might
arise from their use [49–51]. In Europe, iohexol is the preferred
method while in the USA, iothalamate is most commonly used.
Recently, it has been suggested that iohexol may be the most
practical and accurate measure of GFR for a few reasons: it is
stable at a wide range of temperatures and has a very good clini-
cal safety profile; iohexol is more accurate than iothalamate
(which can systematically overestimate GFR by 10–15% due to
tubular secretion); there is very little difference between
Table 1. Reporting of laboratory creatinine measurement and eGFR
equations
Laboratory creatinine measurement (n5252 studiesa)
Creatinine method Jaffe/enzymatic 80 (31.7%)/6 (2.4%)
Not stated 159 (63.1%)
Not measured 7 (2.8%)
Creatinine method IDMS-traceable 34 (13.5%)
Non-IDMS-traceable 5 (2.0%)
Not stated 206 (81.7%)
Not measured 7 (2.8%)
eGFR equationsa (n5363 eGFR equationsb)
Creatinine clearance
(n¼ 9; 2.5%)
BSAd normalized (4/9)
BSA not normalized (3/9)
BSA not stated (2/9)
Cockcroft–Gault
(n¼ 85; 23.4%)
BSA normalized (29/85)
BSA not normalized (28/85)
BSA not stated (28/85)
Non-IDMS-traceable 4-v
MDRD (n¼ 26; 7.2%)
þ Coefficient for AA ethnicity (14/26)
 Coefficient for AA ethnicity (5/26)
Coefficient not stated (7/26)
IDMS-traceable 4-v
MDRD (n¼ 46; 12.7%)
þ Coefficient for AA ethnicity (23/46)
 Coefficient for AA ethnicity (15/46)
Coefficient not stated (8/46)
4-v MDRD (not stated)
(n¼ 74; 20.4%)
þ Coefficient for AA ethnicity (8/74)
 Coefficient for AA ethnicity (9/74)
Coefficient not stated (57/74)
CKD-EPIc (creatinine)
(n¼ 94; 25.9%)
þ Coefficient for AA ethnicity (39/94)
 Coefficient for AA ethnicity (32/94)
Coefficient not stated (23/94)
CKD-EPIc (creatinine þ
cystatin C)
(n¼ 6; 1.7%)
þ Coefficient for AA ethnicity (3/6)
 Coefficient for AA ethnicity (3/6)
Other (n¼ 23; 6.3%) eGFR equation not specified (17/23)
Different eGFR equation used (6/23)
aPercentages rounded to one decimal point and may not sum to 100%.
bOf 252 studies, 21 did not use an eGFR method. Of the remaining studies (231),
some evaluated more than one eGFR method, thus totaling 363 eGFR equations.
cCKD-EPI equation for creatinine alone, or creatinine and cystatin C, or cystatin
C alone.
dBSA (body surface area), normalized to 1.73 m2 [21].
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laboratory techniques for measuring iohexol, for example when
comparing high-performance liquid chromatography with
ultraviolet detection and liquid chromatography-tandem mass
spectrometry, whereas differences have been demonstrated
with iothalamate; and there is an external quality control pro-
gram for iohexol to aid standardizing interlaboratory variation in
measurements which does not exist for iothalamate [48]. It is
critical to contextualize this for SSA, as the 4-v MDRD and CKD-
EPI eGFR equations were all developed using iothalamate and
the coefficient for AA ethnicity would further overestimate GFR.
For the few studies in this review that compared mGFR with
eGFR, the reference methods differed, but none used iothala-
mate and three used iohexol (two intravenously for measure-
ment of plasma excretion and one with dried blood spots)
[12, 15]. While iohexol blood spots may be relatively inferior to
intravenous administration of iohexol, the use of dried blood
spots was possibly the most pragmatic, on the assumption that
access to laboratory support was unlikely in rural Kenya.
This systematic review highlights potential sources of bias
inherent in the assessment of kidney function in clinical studies
in SSA. This has created the opportunity to increase awareness
of the requirements for laboratory-based creatinine assays, the
appropriate choice of estimating equations for calculating GFR
and the appropriate use of diagnostic criteria for CKD. In re-
sponse, we propose an ‘easy to use’ checklist for researchers as
a guide for the reporting of kidney function in SSA (Table 4). We
hope this will minimize bias and strengthen future studies con-
ducted in the region. In addition, inferring population preva-
lence of CKD in SSA from small convenience samples of
individuals at high risk for developing CKD must be cautioned,
as the risk of overestimating CKD is substantial.
While the focus of this systematic review has been clinical
research, the implications of our findings have much broader
application for the management of kidney disease in SSA. This
encompasses individual patient care in the setting of acute and
chronic kidney disease, home-based monitoring of CKD as a
component of an integrated care model for chronic disease
management, and public health policy for screening and pre-
vention of CKD in SSA. None of this can be realized without af-
fordable and accurate diagnostics for kidney disease. To achieve
this, validated population-appropriate estimating equations for
glomerular function need to be prioritized, as well as innovative
approaches to accurate and affordable point of care diagnostics
for assessing kidney function and diagnosing CKD.
SUPPLEMENTARY DATA
Supplementary data are available at ckj online.
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Table 3. Studies evaluating CKD in SSA (n5162)
Number of
studiesa,b n¼ 162, n (%) Parameter used to define CKD
Concordance with KDIGO definition of CKD
Creatinine-based
eGFR equation
Urine protein
or albumin
Confirmation
of chronicity
4 (2.5) Serum creatinine
1 (0.6) Serum creatinine þ urine protein
67 (41.3) Serum creatinine-based eGFR
8 (4.9) Serum creatinine-based eGFR þ follow up mea-
surement at 3 months
22 (13.6) Serum creatinine-based eGFR þ urine albumin
38 (23.5) Serum creatinine-based eGFR þ urine protein
1 (0.6) Serum creatinine-based eGFR þ urine albumin þ
urine protein
12 (7.4) Serum creatinine-based eGFR þ urine protein þ
follow up measurement/s at 3 months
3 (1.9) Urine albumin
5 (3.0) Urine protein
1 (0.6) Urine protein þ follow up measurement at
3 months
aOne study was excluded as the definition used for CKD was unclear.
bPercentages have been rounded to one decimal point and might not sum to 100%.
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